Brief: Sesen Bio Says Strategic Alternatives May Include Sale, A Merger

Carisma Therapeutics

03/05/2022 13:38

May 3 (Reuters) - Sesen Bio Inc  SESN.O :
    * SESEN BIO PROVIDES STRATEGIC UPDATE
    * SESEN BIO INC - POTENTIAL STRATEGIC ALTERNATIVES TO BE
EXPLORED
AND EVALUATED DURING REVIEW PROCESS MAY INCLUDE SALE, A MERGER
    * SESEN BIO INC - POTENTIAL STRATEGIC ALTERNATIVES TO BE
EXPLORED
AND EVALUATED MAY INCLUDE ACQUISITION, A STRATEGIC PARTNERSHIP/
LICENSING, SALE
    * SESEN BIO INC - POTENTIAL STRATEGIC ALTERNATIVES TO BE
EXPLORED
AND EVALUATED MAY INCLUDE OR DIVESTITURE OF SOME OF CO'S
PROPRIETARY TECHNOLOGIES
    * SESEN BIO - PENDING DECISION TO UNDERTAKE ANY STRATEGIC
ALTERNATIVE, CO TO CONTINUE DEVELOPMENT ACTIVITIES ACCORDANCE
WITH EXISTING BUSINESS STRATEGY
    * SESEN BIO INC - PLAN TO REQUEST MEETING WITH FDA IN COMING
WEEKS
TO ALIGN ON REMAINING OUTSTANDING ITEMS RELATED TO ADDITIONAL
PHASE 3 CLINICAL TRIAL
    * SESEN BIO INC - AS OF MARCH 31, 2022, CO HAD $169.8
MILLION IN
CASH AND CASH EQUIVALENTS, NO OUTSTANDING DEBT

Source text for Eikon:  ID:nBw161YnMa 
Further company coverage:  SESN.O 

 ((Reuters.Briefs@thomsonreuters.com;))